soil-transmitted helminthiasis (STH)
Conditions
Interventions
ZP59676
Sponsors
Zero Point Five Therapeutics
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Provide a signed informed consent form from the participant or parent/guardian, and assent by participant (as applicable per local requirements) and understand and agree to comply with required procedures in the study. 2. Male or female, who are 6 months to 59 years old, inclusive, and live in a high STH prevalence area 3. Females of childbearing potential must use an acceptable method of contraception as determined by the Investigator from the initial Screening visit through 35 days after study drug administration. A female is considered to be of childbearing potential from menarche until after menopause (age >45 years with no menses for 12 months without an alternative medical cause) unless permanently sterile. Acceptable methods include abstinence, hormonal contraceptives, intrauterine device/system, vasectomy in the sole male sexual partner, tubal ligation, or double-barrier contraceptive method (male condom with female cervical cap, diaphragm, or sponge) with spermicide. 4. Otherwise healthy based on medical history, physical examination, vital signs, and concomitant medications for inclusion.
Exclusion criteria
Exclusion criteria: 1. Active diarrhea (passage of ?3 loose or liquid stools per day). 2. Children (6 months to 17 years old) with significant wasting (moderate and severe-below minus two standard deviations from median weight for height of reference population). 3. Children (6 months to 17 years old) with a history of seizures. 4. Women who are pregnant or lactating. 5. Hypersensitivity or allergy to ZP5-9676 or any inert ingredients in the chewable formulation or other medications in the benzimidazole class. 6. Taken ZP5-9676 or any other treatment for STH infection within 30 days of screening. 7. Used an investigational medical device within 30 days of screening. 8. Preplanned surgery procedures within 30 days of screening. 9. History of a medical disorder causing difficulty in chewing or swallowing. 10. Participation in any investigational drug (including vaccine) trial within 30 days or six half-lives of the test drug’s biologic activity, whichever is longer, before the start of the study (time of first dose). 11. Participation in an interventional clinical study within 30 days of screening. 12. Any condition that interferes with the ability to understand or comply with the requirements of the study. 13. Any other medical condition, serious illness, or other circumstance that would place the subject at increased risk, as determined by the Investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The incidence of treatment-emergent adverse events EAEs by type ;The incidence of treatment-emergent adverse events EAEs by severity;The incidence of treatment-emergent adverse events EAEs by relatedness | — |
Countries
Ghana
Contacts
Public ContactJoseph Amprey
CEO
Outcome results
None listed